$23.04
-0.92-3.84%
At close: Nov 13, 4:00 PM EST
$23.04
N/A
After Hours: Nov 13, 4:26 PM EST
Caris Life Sciences Inc
CAINASDAQ
Caris Life Sciences (CAI) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $0.05 | $0.02 | 150.0 % |
| Q2 | Aug 5, 2026 | $0 | $0.01 | -100.0 % |
| Q1 | May 7, 2026 | $0 | $-0.02 | 100.0 % |
| Q4 | Feb 26, 2026 | $0.28 | $0.07 | 300.0 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $275.36M | $254.45M | 8.22 % |
| Q2 | Aug 5, 2026 | $263.71M | $236.97M | 11.3 % |
| Q1 | May 7, 2026 | $216.17M | $209.49M | 3.19 % |
| Q4 | Feb 26, 2026 | $292.89M | $280.90M | 4.27 % |
Caris Life Sciences (CAI) last issued guidance on November 4, 2026 for fiscal year 2026. The company guided revenue in the range of $1.04B - $1.05B for the period.
Compared to prior guidance, Caris Life Sciences maintained its revenue forecast from a prior range of $1.03B - $1.04B.
Caris Life Sciences has issued 8 guidance updates between August 12, 2025 and November 4, 2026. During this period, the company raised its outlook 4 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.02 | $0.01 | $-0.02 | $0.07 |
| Actual | $0.05 | $0.00 | $0.00 | $0.28 |
| Surprise | +150.0% | -100.0% | +100.0% | +300.0% |
| Revenue | ||||
| Estimate | $254.4M | $237.0M | $209.5M | $280.9M |
| Actual | $275.4M | $263.7M | $216.2M | $292.9M |
| Surprise | +8.22% | +11.3% | +3.19% | +4.27% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.06 | $0.04 | $0.09 | $0.10 |
| Revenue | ||||
| Consensus | $289.1M | $271.7M | — | — |
